SHOP APOTHEKE EUROPE: Strong growth of everything-but-Rx.

• Everything but Rx grew by 21.6% in the first nine months of 2021.
• Preliminary total sales growth stands at 9.8% for the first nine months of 2021 to EUR 772 million, on track for full-year sales growth guidance.
• A negative start of Q3 due to capacity constraints was offset by recovered growth towards the end of the quarter; Q3 growth -0.3%.
• Number of active customers up 1 million in the first nine months of 2021 to 7.3 million (year-over-year up 1.4 million).

Sevenum, 5 October 2021. SHOP APOTHEKE EUROPE N.V., currently active in seven European countries, has increased sales for the first nine months of 2021 by 9.8% to EUR 772 million, according to preliminary calculations. Sales had been impacted by capacity constraints from May to mid-September, which resulted in preliminary Q3 sales growth of -0.3% to EUR 238 million. The number of active customers increased by 0.2 million to 7.3 million at the end of Q3.

CEO Stefan Feltens: "The move to our new next generation logistics centre was completed by the beginning of September. Our capacity constraints have been resolved. We no longer have a shortage of logistics personnel. This allows us to return to our growth trajectory and to be prepared for further growth in Q4 and 2022. Year to date, we are posting 9.8% growth thanks to continuously strong growth in our non-Rx assortment in our markets across Europe including Germany, which balanced a decrease of 30.6% in Rx sales in 2021 following the end of the Rx bonus in December 2020. We expect the launch of electronic prescriptions (e-Rx) in Germany soon."

In the DACH segment (Germany, Austria, Switzerland), SHOP APOTHEKE EUROPE's Q3 sales were EUR 189 million compared to the previous year's 201 million. 9M sales increased by 4.5% to EUR 618 million after EUR 592 million in 2020. 9M growth of non-Rx stands at 17.4%.

In the International segment (Belgium, France, Italy, the Netherlands), SHOP APOTHEKE EUROPE increased its sales in the third quarter of 2021 by 27.2% to EUR 48 million. 9M sales increased by 37.9% to EUR 154 million after EUR 112 million in 2020.

For the full year 2021, the Management Board of SHOP APOTHEKE EUROPE expects sales growth between 10 and 15% and an adjusted EBITDA margin around break-even.

All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE N.V. will release its 9M interim report 2021 on 2 November 2021. Definitions of non-IFRS terms can be found in the Glossary of the Annual Report 2020 (pages 146 and 147).
 

ABOUT SHOP APOTHEKE EUROPE.
SHOP APOTHEKE EUROPE is one of Europe's leading and fastest-growing online pharmacies, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Paris and Eindhoven, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 100,000 original products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by high quality natural food and health products, low carb products and sports nutrition. Currently, more than 7 million active customers trust SHOP APOTHEKE EUROPE.

Since safe and reliable pharmaceutical advice are top priorities at SHOP APOTHEKE EUROPE, the e-pharmacy provides comprehensive pharmaceutical consulting services.

In preparation for the introduction of electronic prescriptions in Germany in summer 2021, the company will further improve the customer experience with focus on disease-specific digital medication management services following the acquisition of SMARTPATIENT in January 2021. This is a key part of SHOP APOTHEKE EUROPE's strategy to transform itself from a pure online retailer into a truly customer-centric e-pharmacy platform.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and is part of the SDAX stock index.